Cargando…

Acute Hemodynamic Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Diastolic Heart Failure (DILATE-1): A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study

BACKGROUND: Deficient nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate signaling results from endothelial dysfunction and may underlie impaired cardiac relaxation in patients with heart failure with preserved left ventricular ejection fraction (HFpEF) and pulmonary hypertension...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bonderman, Diana, Pretsch, Ingrid, Steringer-Mascherbauer, Regina, Jansa, Pavel, Rosenkranz, Stephan, Tufaro, Caroline, Bojic, Andja, Lam, Carolyn S. P., Frey, Reiner, Ochan Kilama, Michael, Unger, Sigrun, Roessig, Lothar, Lang, Irene M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American College of Chest Physicians 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219342/ https://www.ncbi.nlm.nih.gov/pubmed/24991733 http://dx.doi.org/10.1378/chest.14-0106

Ejemplares similares

Evaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction: Study protocol for a randomized controlled trial
por: Mascherbauer, Julia, et al.
Publicado: (2016)

Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial( )
por: Dachs, Theresa Marie, et al.
Publicado: (2022)

Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat
por: Frey, Reiner, et al.
Publicado: (2017)

Absorption behavior of riociguat: bioavailability, food effects, and dose-proportionality
por: Becker, Corina, et al.
Publicado: (2013)

Effects of omeprazole and AlOH/MgOH on riociguat absorption
por: Becker, Corina, et al.
Publicado: (2013)

Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
por: Frey, Reiner, et al.
Publicado: (2013)

Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment
por: Frey, Reiner, et al.
Publicado: (2013)

Pharmacokinetic interaction of ketoconazole, clarithromycin, and midazolam with riociguat
por: Becker, Corina, et al.
Publicado: (2013)

Bioavailability, pharmacokinetics and safety of riociguat given as an oral suspension or crushed tablet with and without food
por: Saleh, Soundos, et al.
Publicado: (2015)

No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin
por: Frey, Reiner, et al.
Publicado: (2011)

Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults
por: DeJesus, Edwin, et al.
Publicado: (2019)

Epicardial fat volume is inversely correlated with the degree of diastolic dysfunction and outcome in patients with heart failure with preserved ejection fraction
por: Karakus, Gültekin, et al.
Publicado: (2013)

Riociguat for pulmonary arterial hypertension associated with congenital heart disease
por: Rosenkranz, Stephan, et al.
Publicado: (2015)

Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)
por: Ghofrani, Hossein-Ardeschir, et al.
Publicado: (2020)

Effects of age and gender on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat
por: Frey, Reiner, et al.
Publicado: (2013)

Riociguat: Clinical research and evolving role in therapy
por: Klinger, James R., et al.
Publicado: (2020)

Riociguat for pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD): A subgroup analysis from the PATENT studies
por: Stephan, Rosenkranz, et al.
Publicado: (2015)

Pulmonary artery to aorta ratio for the detection of pulmonary hypertension: cardiovascular magnetic resonance and invasive hemodynamics in heart failure with preserved ejection fraction
por: Karakus, Gültekin, et al.
Publicado: (2015)

Gender-related differences in heart failure with preserved ejection fraction
por: Duca, Franz, et al.
Publicado: (2018)

Clinical and hemodynamic benefit of macitentan and riociguat upfront combination in patients with pulmonary arterial hypertension
por: Sulica, Roxana, et al.
Publicado: (2019)

Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
por: Frey, Reiner, et al.
Publicado: (2009)

RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors
por: Hoeper, Marius M., et al.
Publicado: (2017)

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study
por: McLaughlin, Vallerie V., et al.
Publicado: (2017)

Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension
por: Davey, Ryan, et al.
Publicado: (2017)

Extracellular matrix expansion by cardiac magnetic resonance T1 mapping- validation with myocardial biopsy
por: Kammerlander, Andreas, et al.
Publicado: (2015)

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension
por: Kim, Nick H, et al.
Publicado: (2017)

Riociguat: PATENT-1 Study
por: Said, Karim
Publicado: (2014)

Hemodynamic Effects of a Soluble Guanylate Cyclase Stimulator, Riociguat, and an Activator, Cinaciguat, During NO-Modulation in Healthy Pigs
por: Næsheim, Torvind, et al.
Publicado: (2020)

Extracellular volume quantification by cardiac magnetic resonance imaging without hematocrit sampling: Ready for prime time?
por: Kammerlander, Andreas A., et al.
Publicado: (2017)

Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study
por: Simonneau, Gérald, et al.
Publicado: (2020)

The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats
por: Schwabl, Philipp, et al.
Publicado: (2018)

Diffuse myocardial fibrosis by post-contrast T1-time predicts outcome in heart failure with preserved ejection fraction
por: Marzluf, Beatrice A, et al.
Publicado: (2013)

Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Benza, Raymond L., et al.
Publicado: (2022)

Presence of ´isolated´ tricuspid regurgitation should prompt the suspicion of heart failure with preserved ejection fraction
por: Mascherbauer, Julia, et al.
Publicado: (2017)

Population pharmacokinetics of riociguat and its metabolite in patients with chronic thromboembolic pulmonary hypertension from routine clinical practice
por: Michaličková, Danica, et al.
Publicado: (2020)

Beneficial effects of riociguat on hemodynamic responses to exercise in CTEPH patients after balloon pulmonary angioplasty – A randomized controlled study
por: Aoki, Tatsuo, et al.
Publicado: (2020)

Effects of riociguat in severe experimental pulmonary hypertension
por: Kojonazarov, Baktybek, et al.
Publicado: (2011)

Riociguat: Something new in pulmonary hypertension therapeutics?
por: Shanmugam, Elangovan, et al.
Publicado: (2015)

Riociguat in Patients with CTEPH and Advanced Age and/or Comorbidities
por: Barnikel, Michaela, et al.
Publicado: (2022)

Outcome in Heart Failure with Preserved Ejection Fraction: The Role of Myocardial Structure and Right Ventricular Performance
por: Goliasch, Georg, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_pt68nvsia7tip61d0v144ad52b